This is a working overview of amino acid substitution, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-07-16 and is reviewed periodically as new material appears.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Synthetic cyclic heptapeptide |
| Molecular mass | Approximately 1024 g/mol | Depends on counter-ion content |
| Appearance | White to off-white powder | Commonly supplied as a lyophilised solid |
| Solubility | Freely soluble in water | Also dissolves in common aqueous buffers |
| Typical storage | -20 degrees Celsius, desiccated | Protect from light and repeated freeze-thaw |
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
The body of the royal angelfish is moderately elongate and is very compressed. The preorbital bone is convex and has no strong spines. There is 1 prominent spine at an angle at the preopercal. The ventral edge of the interopercle is smooth. The eyes are moderately small along with the mouth that is terminal. The mouth is also protractile. They have a maximum length of 25.0 cm (9.8 in). They have a total of 14 dorsal spines, and 17–19 soft dorsal rays. They have 3 anal spines and 17–19 anal soft rays. They also have 16–17 pectoral fin rays. Their caudal fin is rounded. The precise coloration of this fish can vary as regional differences can occur, most notably in populations from the Indian Ocean, Red Sea, and South Pacific Ocean. A commonality, however, is a body edged in narrow blue-white and orange stripes that are narrow and angle backward. The posterior portion of dorsal fin is black or blue with close-set blue dots, and the posterior portion of anal fin has alternating yellow and blue bands running parallel to body contour. The caudal fin is yellow. Juveniles are colored with a large dark spot on basal portion of the soft dorsal fin. They have been reported of living 15 years. Recent research indicates that the Pygoplites comprises two morphs, with the variants potentially hybridizing at Christmas Island.
=== Long term === If a person with type 1 diabetes who has diabulimia has the disease for more than a short time—usually due to alternating phases during which insulin is injected properly and relapses during which they have diabulimia—then the following longer-term symptoms can be expected:
==== Dietary recommendations ==== The U.S. Institute of Medicine (IOM) updated Estimated Average Requirements (EARs) and Recommended Dietary Allowances (RDAs) for zinc in 2001. The current EARs for zinc for women and men ages 14 and up is 6.8 and 9.4 mg/day, respectively. The RDAs are 8 and 11 mg/day. RDAs are higher than EARs so as to identify amounts that will cover people with higher than average requirements. RDA for pregnancy is 11 mg/day. RDA for lactation is 12 mg/day. For infants up to 12 months the RDA is 3 mg/day. For children ages 1–13 years the RDA increases with age from 3 to 8 mg/day. As for safety, the IOM sets Tolerable upper intake levels (ULs) for vitamins and minerals when evidence is sufficient. In the case of zinc the adult UL is 40 mg/day including both food and supplements combined (lower for children). Collectively the EARs, RDAs, AIs and ULs are referred to as Dietary Reference Intakes (DRIs). The European Food Safety Authority (EFSA) refers to the collective set of information as Dietary Reference Values, with Population Reference Intake (PRI) instead of RDA, and Average Requirement instead of EAR. AI and UL are defined the same as in the United States. For people ages 18 and older the PRI calculations are complex, as the EFSA has set higher and higher values as the phytate content of the diet increases. For women, PRIs increase from 7.5 to 12.7 mg/day as phytate intake increases from 300 to 1200 mg/day; for men the range is 9.4 to 16.3 mg/day. These PRIs are higher than the U.S. RDAs.
In the Philippines, the Maoist-oriented Communist Party of the Philippines, through its armed wing the New People's Army, has since 1968 sought to overthrow oligarchic state structures in the Philippines; under the administration, however, of an otherwise-sympathetic Rodrigo Duterte, its armed attacks were greatly diminished. By contrast, the original Marxist–Leninist party founded in 1930 has preferred nonviolent parliamentary struggle through participation in general elections.
Kyle Hardingham (born 1 September 1988) is a former professional Australian rules footballer who played for the Essendon Football Club in the Australian Football League (AFL). Hardingham was selected by Essendon with the seventh pick in the 2010 AFL Pre-Season Draft. Originally from East Fremantle in the WAFL, he represented Western Australia in the state game against South Australia in 2009. He made his AFL debut against North Melbourne in round 17 of the 2010 AFL season, kicking four goals, helping Essendon achieve an upset victory by 3 points. The following Friday night, he kicked two goals in a win against St Kilda. He managed to kick two goals once again in the next game, a 76-point loss to Carlton, although he also kicked two behinds as part of the wayward kicking by the entire Essendon team, which managed 9.19 for the night. Hardingham was delisted at the conclusion of the 2014 AFL season. He remained with Essendon as a VFL-listed player in its reserves team in 2016. Hardingham, along with 33 other Essendon players, was found guilty of using a banned performance-enhancing substance, thymosin beta-4, as part of Essendon's sports supplements program during the 2012 season. He and his teammates were initially found not guilty in March 2015 by the AFL Anti-Doping Tribunal, but a guilty verdict was returned in January 2016 after an appeal by the World Anti-Doping Agency. He was suspended for two years which, with backdating, ended in November 2016; as a result, he served approximately fourteen months of his suspension and missed the entire 2016 season.
Sources: en.wikipedia.org
=== Pharmacodynamics === Propofol's proposed mechanism of actionsuggests potentiation of GABAA receptor activity by acting as a GABAA receptor positive allosteric modulator, which slows receptor channel-closing time. At high doses, propofol may activate GABAA receptors in the absence of GABA, behaving as a GABAA receptor agonist as well. Propofol analogs also seem to act as sodium channel blockers. Some research suggested significant endocannabinoid system contributions to propofol's unique anesthetic properties, as endocannabinoids also play an important role in the physiologic control of sleep, pain processing and emesis. An EEG study on patients undergoing general anesthesia with propofol found that it causes a prominent reduction in the brain's information integration capacity. A 2026 study using Neuropixels detected hippocampus activity distinguishing sounds and recognizing language under general anesthesia with propofol. Propofol inhibits fatty acid amide hydrolase, which metabolizes the endocannabinoid anandamide (AEA). Activation of the endocannabinoid system by propofol, possibly via inhibition of AEA catabolism, generates a significant increase in the whole-brain content of AEA, contributing to the sedative properties of propofol via CB1 receptor activation. This may explain the psychotomimetic and antiemetic properties of propofol.
For instance, the rare alternative start codon CTG codes for Methionine when used as a start codon, and for Leucine in all other positions. Example: Condensed translation table for the Standard Genetic Code (from the NCBI Taxonomy webpage).
Tianeptine/naloxone reached phase 2 clinical trials for major depressive disorder and phase 1 clinical trials for post-traumatic stress disorders and cognition dysfunction related to corticosteroid use prior to the discontinuation of its development. Its development was discontinued for all indications in October 2023 due to lack of effectiveness for major depressive disorder in a phase 2 clinical trial.
Geochronology is the science of determining the age of rocks, fossils, and sediments using signatures inherent in the rocks themselves. Absolute geochronology can be accomplished through radioactive isotopes, whereas relative geochronology is provided by tools such as paleomagnetism and stable isotope ratios. By combining multiple geochronological (and biostratigraphic) indicators the precision of the recovered age can be improved. Geochronology is different in application from biostratigraphy, which is the science of assigning sedimentary rocks to a known geological period via describing, cataloging and comparing fossil floral and faunal assemblages. Biostratigraphy does not directly provide an absolute age determination of a rock, but merely places it within an interval of time at which that fossil assemblage is known to have coexisted. Both disciplines work together hand in hand, however, to the point where they share the same system of naming strata (rock layers) and the time spans utilized to classify sublayers within a stratum. The science of geochronology is the prime tool used in the discipline of chronostratigraphy, which attempts to derive absolute age dates for all fossil assemblages and determine the geologic history of the Earth and extraterrestrial bodies.
Sources: en.wikipedia.org
The sinoatrial node (also known as the sinuatrial node, SA node, sinus node or Keith–Flack node) is an oval shaped region of special cardiac muscle in the upper back wall of the right atrium made up of cells known as pacemaker cells. The sinus node is approximately 15 mm long, 3 mm wide, and 1 mm thick, located directly below and to the side of the superior vena cava. These cells produce an electrical impulse known as a cardiac action potential that travels through the electrical conduction system of the heart, causing it to contract. In a healthy heart, the SA node continuously produces action potentials, setting the rhythm of the heart (sinus rhythm), and so is known as the heart's natural pacemaker. The rate of action potentials produced (and therefore the heart rate) is influenced by the nerves that supply it.
==== Structural impacts on hydrogen storage capacity ==== To date, hydrogen storage in MOFs at room temperature is a battle between maximizing storage capacity and maintaining reasonable desorption rates, while conserving the integrity of the adsorbent framework (e.g., completely evacuating pores, preserving the MOF structure, etc.) over many cycles. There are two major strategies governing the design of MOFs for hydrogen storage:
When the Communist revolution successfully overthrew the dictatorial government of Fulgencio Batista, the Grand Lodge of Cuba suspended all of its activities. According to Grand Master Juan Tarajano-Gonzales, Castro's government seized the Masonic Temple in Havana, after which Grand Master Tarajano-Gonzalez and Grand Secretary Eduardo R. Lopez Bobadilla fled the country to seek exile in Florida.
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide and an analogue of alpha-melanocyte-stimulating hormone. The molecule is produced by chemical synthesis rather than extracted from a biological source.
It is shorter than the native hormone and carries a cyclic constraint that improves stability. These changes raise receptor potency and slow breakdown relative to the naturally occurring peptide.
Published accounts date its development to the 1980s, when researchers were generating analogues of melanocyte-stimulating hormone. That work aimed to produce more stable compounds for studying pigmentation biology.
It is a synthetic cyclic heptapeptide modelled on alpha-melanocyte-stimulating hormone. A lactam bridge links two side chains, forming a ring that stabilises the molecule against proteolysis. It belongs to the broader melanocortin peptide family.